secwatch.observer — SEC 8-K summary
======================================

Issuer:     KALA BIO, Inc. (KALA)
CIK:        0001479419
Form:       8-K
Filed at:   2023-03-27T23:59:59+00:00
Accession:  0001558370-23-004634
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Kala Pharma reports positive safety data in CHASE Phase 2b trial of KPI-012; second cohort initiated
--------------------------------------------------------------------------------

- Both patients in open-label first cohort (high dose 3 U/mL QID) completed at least 1 week with no safety issues.
- Second cohort is randomized, double-masked, vehicle-controlled study of ~90 patients testing two doses vs vehicle for 56 days.
- Primary endpoint is complete healing of PCED measured by corneal fluorescein staining.
- Topline safety and efficacy data expected in Q1 2024; positive results could support first pivotal trial for BLA.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1479419/000155837023004634/0001558370-23-004634-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1479419/000155837023004634/kala-20230327x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-23-004634

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer